Navigation Links
Approval of Stelara for Psoriatic Arthritis and for Self-Administration is Likely to Help the Drug's Uptake in the Psoriasis Market

BURLINGTON, Mass., Dec. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that—following the approval of Janssen Biotech's Stelara for psoriatic arthritis—about one-third of surveyed dermatologists expect to at least modestly increase the prescribing of Stelara as a first-line biologic. In addition, following the FDA's approval of self-administration for Stelara, 26 percent of surveyed dermatologists report that they would at least modestly increase prescribing Stelara as a first-line biologic, suggesting that convenience of self-administration could further increase Stelara's uptake.

(Logo: )

The new U.S. Physician & Payer Forum report entitled Will the Anticipated Approval and Reimbursement of Novel Orals Result in a Major Shift in Biologics Prescribing in Psoriasis? finds that, among available biologics for psoriasis, Stelara currently has the highest level of formulary exclusion and National Drug Code blockage. However, following Stelara's approval for the treatment of psoriatic arthritis and for self-administration, more than half of surveyed Managed Care Organization pharmacy and medical directors who currently cover Stelara predict their plans are likely to move the drug to a preferred tier. Also, among those surveyed payers who do not currently cover Stelara, 83 percent indicate a willingness to start including Stelara on their formulary.

The psoriasis market is also set to incorporate Celgene's apremilast, an oral Phosphodiesterase-4 inhibitor expected to be approved in 2014. The findings reveal that if apremilast is placed on a preferred tier, 72 percent of surveyed dermatologists expect to prescribe this therapy. Among the dermatologists who expect to prescribe apremilast, 40 percent would consider prescribing it as a first-line systemic therapy if apremilast is in a similar formulary position as Amgen/Stiefel/Pfizer's Enbrel and AbbVie/Eisai's Humira. This finding is not surprising, given the drug's benign safety profile in trials reported to date and the convenience of the drug's oral formulation. This, combined with the agent's modest efficacy profile compared with Enbrel, suggests that apremilast's best use is for patients with less severe psoriasis than those who are biologics candidates. In addition, more than 70 percent of surveyed payers who plan to cover apremilast would consider reimbursing it on a preferred tier only if the drug is priced at a substantial discount (greater than 40 percent) to Humira.

"Apremilast's oral formulation and its likely lower price compared with biologics would persuade dermatologists to prescribe apremilast," said Decision Resources Analyst Eun-Jin Yang, Ph.D. "However, surveyed dermatologists who indicate a willingness to prescribe the drug anticipate that dissatisfaction with apremilast's efficacy profile and expectation of poor formulary coverage or a high copay will constrain prescribing of the drug."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. USANA Probiotic Product Gets Seal Of Approval From
2. The Approval Of The First Biosimilar Monoclonal Antibody In Europe Has Major Implications For 2014 And Beyond
3. TriReme Medical and Japanese Partner Century Medical, Inc., Receive Shonin Approval for GliderXtreme PTA Catheter in Japan
4. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
5. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
6. Seventh Sense Biosystems Receives CE Mark Approval for its Touch Activated Phlebotomy Blood Collection and Testing System
7. BD Rx Announces FDA Approval of High-Demand Injectable for Pain Management
8. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
9. IGI Laboratories, Inc. Receives Formal US FDA Approval For Site Transfer Of Econazole Nitrate
10. The EE Times Community Weighs in on Brain Implants as it Nears FDA Approval
11. John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001(EMERGE) Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma (MCL) Patients
Post Your Comments:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
Breaking Medicine News(10 mins):